Can Pfizer Bank On New Immunotherapy Bavencio For Growth?
August 17, 2017 at 13:59 PM EDT
As demand for immuno-oncology drugs and their combinations rises, Pfizer, Inc.’s newly approved immunotherapy, Bavencio, is being considered a significant top-line driver for this New York-based pharma giant.
